<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344158</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-AK105-III-02</org_study_id>
    <nct_id>NCT04344158</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105
      injection combined with Anlotinib Hydrochloride Capsules versus Sorafenib. Patients are
      treated with AK105 injection combined with Anlotinib Hydrochloride Capsules or Sorafenib,
      with 2:1 random ratio. Every 21 days is a treatment cycle.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>OS defined as the time from the first dose to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate（ORR）</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate（DCR）</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">648</enrollment>
  <condition>Advanced Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>AK105 combined with Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK105 200mg intravenously (IV) on day 1 of each 21-day cycle plus Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib Tosylate Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK105 Injection</intervention_name>
    <description>AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.</description>
    <arm_group_label>AK105 combined with Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride Capsules</intervention_name>
    <description>Anlotinib capsules 10mg given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
    <arm_group_label>AK105 combined with Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate Tablets</intervention_name>
    <description>Sorafenib Tosylate Tablets 400mg given orally, twice daily in 21-day cycle.</description>
    <arm_group_label>Sorafenib Tosylate Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. 18-75 years old; Eastern Cooperative Oncology Group (ECOG) performance status score
             of 0 or 1; Life expectancy ≥ 3 months.

             2. Histopathology or cytology confirmed as HCC. 3. Has not received any systematic
             treatment for HCC. 4. Stage B or C in the Barcelona Clinic Liver Cancer (BCLC)
             classification, and is not suitable for surgery or local treatment, or progress after
             surgery or local treatment.

             5. Child-Pugh liver function classification : A or B (≤7 points). 6. Central nervous
             system metastasis has no clinical symptoms or is stable at least 4 weeks after
             treatment.

             7. Quantification of HBV DNA &lt;500IU/ml or 2500 Copys/ml, and anti-HBV therapy should
             be given for at least 2 weeks before the first administration; Quantification of HCV
             RNA is positive must complete antiviral therapy at least 1 month before the first
             administration.

             8. Patients who progress after local treatment should be at least 4 weeks after the
             end of local treatment.

             9. Radiotherapy for bone metastases accompanied by clinical symptoms must be completed
             at least 2 weeks before the first administration.

             10. Has at least one measurable lesion. 11. Adequate organ function. 12. Male or
             female subjects should agree to use an adequate method of contraception starting with
             the first dose of study therapy through 6 months after the last dose of study (such as
             intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women,
             and a negative pregnancy test are received within 7 days before the randomization.

             13.Understood and signed an informed consent form.

        Exclusion Criteria:

          -  1. Histopathology or cytology confirmed as fibrolamellar hepatocellular carcinoma,
             sarcomatoid hepatocellular carcinoma, hepatobiliary cell carcinoma, mixed liver
             cancer, etc.

             2. Has used anti-angiogenic drugs such as anlotinib, apatinib, lenvatinib, sorafenib,
             sunitinib, bevacizumab, or related immunotherapy drugs for PD-1, PD-L1, etc.

             3. Has received systemic treatment such as chemotherapy and biological therapy. 4. Has
             a history of hepatic encephalopathy. 5. According to imaging examination, the portal
             vein has invasion of cancer embolus, inferior vena cava or heart involvement.

             6. Hepatitis B with hepatitis C or hepatitis D infection. 7. Has received or planned
             to receive organ transplantation. 8. Has other malignant tumors within 5 years. 9. Has
             multiple factors affecting oral medication. 10. Has uncontrolled pleural effusion,
             pericardial effusion, or ascites requiring repeated drainage.

             11. Has any bleeding or bleeding events ≥grade 3 in the first 4 weeks before the first
             administration.

             12. Has unhealed wounds, fractures, active gastric and duodenal ulcers, positive
             continuous fecal occult blood, ulcerative colitis in the first 4 weeks before the
             first administration.

             13. Has adverse events caused by previous therapy except alopecia that did not recover
             to ≤grade 1.

             14. Has received surgery, or unhealed wounds within 4 weeks before the first
             administration.

             15. Has drug abuse history that unable to abstain from or mental disorders. 16. Has
             any serious and / or uncontrolled disease. 17. Has received vaccination or attenuated
             vaccine within 4 weeks prior to the first administration.

             18. Has received anti-tumor Traditional Chinese Medicine within 2 weeks before the
             first administration.

             19. Severe hypersensitivity after administration of other monoclonal antibodies.

             20. Has any active autoimmune disease or history of autoimmune disease.
             21.Immunosuppressant or systemic or absorbable local hormone therapy is required to
             achieve the aim of immunosuppression (dose &amp;gt; 10mg/ day prednisone or other
             therapeutic hormones) and is still used within 2 weeks after the first administration.

             22.Has participated in other anticancer drug clinical trials within 4 weeks. 23.Portal
             hypertension with high risk of hemorrhage, or have red sign confirmed by gastroscopy.

             24.According to the judgement of the investigators, there are other factors that may
             lead to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fan, Doctor</last_name>
    <phone>021-31587861</phone>
    <email>fan.jia@zs-hospital.sh.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Bengbu Medical College</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rui Wang, Master</last_name>
      <email>ruiwang1011@163.com</email>
    </contact>
    <investigator>
      <last_name>Rui Wang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weidong Jia, Doctor</last_name>
      <email>jwd1968@sina.com</email>
    </contact>
    <investigator>
      <last_name>Weidong Jia, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hu Liu, Doctor</last_name>
      <email>drliuhu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Hu Liu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital.Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinglong Chen, Master</last_name>
      <email>240988122@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jinglong Chen, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital.Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bin Xu, Doctor</last_name>
      <email>xubin1016@126.com</email>
    </contact>
    <investigator>
      <last_name>Bin Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunyi Hao, Doctor</last_name>
      <email>haochunyi@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Chunyi Hao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Haitao Zhao, Doctor</last_name>
      <email>pumchzht@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Haitao Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese Pla General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shunchang Jiao, Master</last_name>
      <phone>010-66939409</phone>
      <email>jiaosc@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Shunchang Jiao, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuewei Zhang, Doctor</last_name>
      <email>zhangyuewei1121@sina.com</email>
    </contact>
    <investigator>
      <last_name>Yuewei Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital.Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianjun Leng, Doctor</last_name>
      <email>dr_leng@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianjun Leng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hong Ren, Master</last_name>
      <email>renhong0531@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Hong Ren, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shangeng Weng, Doctor</last_name>
      <email>shangeng@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shangeng Weng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenchang Yu, Doctor</last_name>
      <email>yuwenchang1818@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Wenchang Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaorong Mao, Doctor</last_name>
      <email>mxr2013@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiaorong Mao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Wuwei Tumour Hospital</name>
      <address>
        <city>Wuwei</city>
        <state>Gansu</state>
        <zip>733000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenhua Zhang</last_name>
      <email>925944468@qq.com</email>
    </contact>
    <investigator>
      <last_name>Wenhua Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancar Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Minshan Chen, Doctor</last_name>
      <email>cms64@163.com</email>
    </contact>
    <investigator>
      <last_name>Minshan Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhixiang Jian, Doctor</last_name>
      <email>Jzx_118@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhixiang Jian, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital，Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenbo Guo, Doctor</last_name>
      <email>zsyyyb@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wenbo Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510289</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yajin Chen, Doctor</last_name>
      <email>cyj0509@126.com</email>
    </contact>
    <investigator>
      <last_name>Yajin Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital，Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenbo Guo, Doctor</last_name>
      <email>zsyyyb@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wenbo Guo, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Bangde Xiang, Doctor</last_name>
      <email>Xiangbangde@163.com</email>
    </contact>
    <investigator>
      <last_name>Bangde Xiang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jie Ma, Doctor</last_name>
      <email>majie086@163.com</email>
    </contact>
    <investigator>
      <last_name>Jie Ma, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jinfang Zheng, Doctor</last_name>
      <email>zhenjf2000@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinfang Zheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cangzhou Central Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <zip>061001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Sichen Wei, Master</last_name>
      <email>ssw1968@126.com</email>
    </contact>
    <investigator>
      <last_name>Sichen Wei, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuemin Nan, Doctor</last_name>
      <email>nanyuemin@163.com</email>
    </contact>
    <investigator>
      <last_name>Yuemin Nan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuxian Bai, Doctor</last_name>
      <email>bai_yuxian@126.com</email>
    </contact>
    <investigator>
      <last_name>Yuxian Bai, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Province People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shundong Cang, Doctor</last_name>
      <email>cangshundong@163.com</email>
    </contact>
    <investigator>
      <last_name>Shundong Cang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hailiang Li, Doctor</last_name>
      <email>cjr.lihailiang@vip.163.com</email>
    </contact>
    <investigator>
      <last_name>Hailiang Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhiming Wang, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Zhiming Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancar Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shanzhi Gu, Master</last_name>
      <email>105575191@qq.com</email>
    </contact>
    <investigator>
      <last_name>Shanzhi Gu, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhiqiang Meng, Doctor</last_name>
      <email>mengfudan2018@yeah.net</email>
    </contact>
    <investigator>
      <last_name>Zhiqiang Meng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fuadn University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia Fan, Doctor</last_name>
      <phone>021-31587861</phone>
      <email>fan.jia@zs-hospital.sh.cn</email>
    </contact>
    <investigator>
      <last_name>Jia Fan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhenggang Ren, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuangsuo Dang, Doctor</last_name>
      <email>dang212@126.com</email>
    </contact>
    <investigator>
      <last_name>Shuangsuo Dang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital of the Fourth Military Medical University of the People's Liberation Army of China</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianqi Lian, Doctor</last_name>
      <email>Lianjq@fuiniu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jianqi Lian, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Yang, Doctor</last_name>
      <email>yang88@xjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Wei Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Cancer Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qinyang Zhang, Bachelor</last_name>
      <email>ZhangQinYang88@163.com</email>
    </contact>
    <investigator>
      <last_name>Qinyang Zhang, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China School of Medical Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chengdu University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610081</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianrong Wu, Bachelor</last_name>
      <email>2401403457@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jianrong Wu, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancar institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianqiang Song, Doctor</last_name>
      <email>tjchi@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tianqiang Song, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Han, Doctor</last_name>
      <email>hantaomd@126.com</email>
    </contact>
    <investigator>
      <last_name>Tao Han, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yamin Zhang, Doctor</last_name>
      <email>zhangyamin@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yamin Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia Li, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Jia Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaobo Lu, Doctor</last_name>
      <email>Xjykdluxiaobo@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiaobo Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

